[Reporter¡¯s View] Why set deadlines in pricing negotiations
By Eo, Yun-Ho | translator Alice Kang
22.02.16 17:10:59
°¡³ª´Ù¶ó
0
This question arises with the uprise of deadline extensions being made in the drug pricing negotiations between the National Health Insurance Service and pharmaceutical companies for reimbursement listing or reimbursed indication extensions. Simply put, too many ¡®exceptions¡¯ are being made.
When the drug pricing negotiation period for the 3rd generation lung cancer treatment ¡®Tagrisso (Osimertinib)¡¯ was extended five years ago, the media had described the extension as ¡®exceptional¡¯ or ¡®unprecedented.¡¯ However, so many drugs, especially antica
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)